Cargando…
Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
Subcutaneous secukinumab (Cosentyx(®)) is a recombinant, fully human, immunoglobulin (Ig) G1κ monoclonal antibody targeted against interleukin (IL)-17A, a proinflammatory cytokine involved in the pathogenesis of psoriasis. Secukinumab is approved in the EU and the USA for the treatment of moderate t...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599386/ https://www.ncbi.nlm.nih.gov/pubmed/34665445 http://dx.doi.org/10.1007/s40272-021-00476-w |